Rigel Pharmaceuticals, Inc. (RIGL) Financial Analysis & Valuation | Quarter Chart
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocy... more
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $901.42M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Raul R. Rodriguez |
| IPO Date | 2000-11-29 | CAGR | 14.36% |
| Employees | 173 | Website | www.rigel.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.02% | Total Yield | 0.02% |
RIGL chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $856.86M | P/E | 12.43 | Forward P/E | 9.72 | PEG | -0.04 |
| P/S | 845.97 | P/B | 551.25 | P/CF | 2941.37 | P/FCF | 2933.76 |
| Sales | $276.79M | Sales 1Y | 3.31% | Sales 3Y | 118.55% | Sales 5Y | 92.05% |
| EPS | $3.92 | EPS 1Y | 201.66% | EPS 3Y | -848.62% | EPS 5Y | -3122.22% |
| Sales QoQ | 33.81% | EPS QoQ | 100% | Sales QoQ Avg | -3.28% | EPS QoQ Avg | 193.79% |
| Gross Margin | 91.39% | Operating Margin | 31.45% | Profit Margin | 116.3% | ROCE | 20.45% |
| ROA | 62% | ROE | 96% | Altman Z Score | 4.1 | Piotroski Score | 4 |
| Current Ratio | 1.95 | Quick Ratio | 1.79 | Cash Ratio | 0.64 | Op. CF Ratio | 0.32 |
| Debt/Equity | 0.09 | Debt/Assets | 0.08 | Lt Debt/Equity | 0 | Lt Debt/Cap. | — |
| Intrst Cov. | 15 | Inventory Turnover | 1.66 | Asset Turnover | 0.53 | Receivables Turnover | 4.94 |
| Enterprise Value | $856.86M | P/E Ratio | 12.43 |
| Forward P/E | 9.72 | PEG Ratio | -0.04 |
| P/S Ratio | 845.97 | P/B Ratio | 551.25 |
| P/CF Ratio | 2941.37 | P/FCF Ratio | 2933.76 |
| EPS | $3.92 | EPS Growth 1Y | 201.66% |
| EPS Growth 3Y | -848.62% | EPS Growth 5Y | -3122.22% |
| Revenue Growth 1Y | 3.31% | Gross Margin | 91.39% |
| Operating Margin | 31.45% | Profit Margin | 116.3% |
| ROE | 96% | ROA | 62% |
| ROCE | 20.45% | Current Ratio | 1.95 |
| Quick Ratio | 1.79 | Cash Ratio | 0.64 |
| Debt/Equity | 0.09 | Interest Coverage | 15 |
| Altman Z Score | 4.1 | Piotroski Score | 4 |
Rigel Pharmaceuticals, Inc. (RIGL) valuation & financials
Rigel Pharmaceuticals, Inc. (RIGL) has a market capitalization of $901.42M and trades at a price-to-earnings ratio of 12.4. It operates in the Healthcare sector (Biotechnology).
Rigel Pharmaceuticals, Inc.'s revenue grew +3.3% over the last year.
Rigel Pharmaceuticals, Inc.'s next earnings report is scheduled for November 3, 2026 (provider scheduled date); analysts estimate EPS of $0.92. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)